216976-30-6

Usage

Chemical Properties

Off-white crystalline

InChI:InChI:1S/C8H6FN/c1-6-2-7(5-10)4-8(9)3-6/h2-4H,1H3

Upstream product

• 189628-39-5 3-fluoro-5-methylbenzaldehyde 

Downstream Products

• 1246526-80-6 tert-butyl N-{3-[amino(hydroxyimino)methyl]-5-fluorobenzyl}-N-methylglycinate 
• 1246526-79-3 tert-butyl N-(3-cyano-5-fluorobenzyl)-N-methylglycinate 
• 1261450-40-1 3-(aminomethyl)-5-fluorobenzonitrile 
• 853368-35-1 3-(bromomethyl)-5-fluorobenzonitrile 
• 1026751-60-9 2-(3-Fluoro-5-methyl-phenyl)-1-(4-methanesulfonyl-phenyl)-4-trifluoromethyl-4,5-dihydro-1H-imidazol-4-ol 
• 177661-49-3 2-(3-fluoro-5-methylphenyl)-1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazole 

Relevant academic research and scientific papers

Copper-Mediated Fluorination of Aryl Trisiloxanes with Nucleophilic Fluoride

A method for the nucleophilic fluorination of heptamethyl aryl trisiloxanes to form fluoroarenes is reported. The reaction proceeds in the presence of Cu(OTf)2 and KHF2 as the fluoride source under mild conditions for a broad range of heptamethyltrisiloxyarenes with high functional group tolerance. The combination of this method with the silylation of aryl C?H bonds enables the regioselective fluorination of non-activated arenes controlled by steric effects following a two-step protocol.

1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents

Series of 1,2-diarylimidazoles has been synthesized and found to contain highly potent and selective inhibitors of the human COX-2 enzyme. The paper describes a short synthesis of the target 1,2-diarylimidazoles starting with aryl nitriles. Different portions of the diarylimidazole (I) were modified to establish SAR. Systematic variations of the substituents in the aryl ring B have yielded very potent (IC50 = 10-100 nm) and selective (1000-12500) inhibitors of the COX-2 enzyme. The study on the influence of substituents in the imidazole ring established that a CF3 group at position 4 gives the optimum oral activity. A number of the diarylimidazoles showed excellent inhibition in the adjuvant induced arthritis model (e.g., ED50 = 0.02 mpk for 22 and 34). The diarylimidazoles are also potent inhibitors of carrageenan-induced edema (ED50 = 9-30 mpk) and hyperalgesia (ED50 = 11- 40 mpk). Several orally active diarylimidazoles show no GI toxicity in the rat and mouse up to 200 mpk.